129 related articles for article (PubMed ID: 38427614)
21. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
22. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
23. Multimodal Targeted Nanoparticle-Based Delivery System for Pancreatic Tumor Imaging in Cellular and Animal Models.
Medina OP; Tower RJ; Medina TP; Ashkenani F; Appold L; Bötcher M; Huber L; Will O; Ling Q; Hauser C; Rohwedder A; Heneweer C; Peschke E; Hövener JB; Lüdtke-Buzug K; Boretius S; Mentlein R; Kairemo K; Glüer CC; Sebens S; Kalthoff H
Curr Pharm Des; 2022; 28(4):313-323. PubMed ID: 32679012
[TBL] [Abstract][Full Text] [Related]
24. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
25. A prospective single-center protocol for using near-infrared fluorescence imaging with indocyanine green during staging laparoscopy to detect small metastasis from pancreatic cancer.
Shirakawa S; Toyama H; Kido M; Fukumoto T
BMC Surg; 2019 Nov; 19(1):165. PubMed ID: 31699083
[TBL] [Abstract][Full Text] [Related]
26. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
27. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer.
Liu SH; Hong Y; Markowiak S; Sanchez R; Creeden J; Nemunaitis J; Kalinoski A; Willey J; Erhardt P; Lee J; van Dam M; Brunicardi FC
Cancer Lett; 2019 Aug; 457():10-19. PubMed ID: 31059751
[TBL] [Abstract][Full Text] [Related]
28. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
[TBL] [Abstract][Full Text] [Related]
29. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
31. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
34. An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer.
Wang Q; Wang J; Yan H; Li Z; Wang K; Kang F; Tian J; Zhao X; Yun SH
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1765-1779. PubMed ID: 36692541
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
36. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
37. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.
Heid I; Trajkovic-Arsic M; Lohöfer F; Kaissis G; Harder FN; Mayer M; Topping GJ; Jungmann F; Crone B; Wildgruber M; Karst U; Liotta L; Algül H; Yen HY; Steiger K; Weichert W; Siveke JT; Makowski MR; Braren RF
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):115-129. PubMed ID: 36074156
[TBL] [Abstract][Full Text] [Related]
38. Targeting of an antecedent proteinase by an activatable probe with deep tissue penetration facilitates early visualization and dynamic malignancy evaluation of orthotopic pancreatic ductal adenocarcinoma (PDAC).
Xu T; Chang D; Cai Y; Min S; Ma Y; Mao H; Ju S
Biomater Sci; 2019 Aug; 7(8):3320-3333. PubMed ID: 31210201
[TBL] [Abstract][Full Text] [Related]
39. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
[TBL] [Abstract][Full Text] [Related]
40. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.
Tummers WS; Miller SE; Teraphongphom NT; Gomez A; Steinberg I; Huland DM; Hong S; Kothapalli SR; Hasan A; Ertsey R; Bonsing BA; Vahrmeijer AL; Swijnenburg RJ; Longacre TA; Fisher GA; Gambhir SS; Poultsides GA; Rosenthal EL
Ann Surg Oncol; 2018 Jul; 25(7):1880-1888. PubMed ID: 29667116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
